Chongqing Bovax

Chongqing Bovax Biopharmaceutical is a Chinese biotechnology company specializing in the research, development, and industrial production of recombinant protein vaccines and drugs. As a wholly-owned subsidiary of Shanghai Bovax Biotechnology, the company operates a large-scale manufacturing base in Chongqing BioPark, focusing on the industrialization of prophylactic vaccines. Its lead programs include 4-valent and 9-valent human papillomavirus (HPV) vaccines, both of which are in Phase 3 clinical trials. The company utilizes advanced Virus-Like Particles (VLPs) technology and a proprietary Hansenula polymorpha expression system to develop a diverse pipeline targeting infectious diseases and cancers. Chongqing Bovax is positioned as a key player in China's domestic vaccine market, aiming to provide high-quality, affordable alternatives to imported products.